Fisher Asset Management LLC Trims Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Fisher Asset Management LLC trimmed its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 4.7% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 3,182,617 shares of the biotechnology company's stock after selling 155,445 shares during the period. Fisher Asset Management LLC owned 1.54% of BioCryst Pharmaceuticals worth $23,933,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in BCRX. Creative Planning increased its position in BioCryst Pharmaceuticals by 5.9% in the 3rd quarter. Creative Planning now owns 49,347 shares of the biotechnology company's stock valued at $375,000 after acquiring an additional 2,734 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of BioCryst Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company's stock valued at $57,000 after purchasing an additional 1,322 shares during the period. Wealth Enhancement Advisory Services LLC raised its stake in shares of BioCryst Pharmaceuticals by 44.5% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 17,344 shares of the biotechnology company's stock worth $132,000 after purchasing an additional 5,340 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in shares of BioCryst Pharmaceuticals by 1,058.1% during the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company's stock worth $3,127,000 after purchasing an additional 375,890 shares during the period. Finally, Aigen Investment Management LP grew its position in BioCryst Pharmaceuticals by 75.0% in the 3rd quarter. Aigen Investment Management LP now owns 28,661 shares of the biotechnology company's stock valued at $218,000 after buying an additional 12,280 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company's stock.

Remove Ads

Analyst Ratings Changes

BCRX has been the subject of a number of analyst reports. HC Wainwright restated a "buy" rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. JMP Securities restated a "market outperform" rating and issued a $18.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Evercore ISI boosted their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an "outperform" rating in a research report on Monday, January 13th. Royal Bank of Canada reissued an "outperform" rating and issued a $11.00 price target (up from $10.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Finally, Needham & Company LLC increased their price objective on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a "buy" rating in a research report on Monday, January 13th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, BioCryst Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $15.57.

BioCryst Pharmaceuticals Stock Performance

BCRX stock traded down $0.17 during midday trading on Friday, hitting $7.69. 4,111,289 shares of the stock were exchanged, compared to its average volume of 2,772,613. The stock's 50-day moving average price is $8.15 and its 200-day moving average price is $7.87. The stock has a market cap of $1.61 billion, a price-to-earnings ratio of -12.61 and a beta of 1.75. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $4.03 and a fifty-two week high of $9.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. During the same period in the previous year, the business earned $0.28 earnings per share. The firm's revenue was up 40.8% on a year-over-year basis. Research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.